Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance.

Previous studies in vivo have shown that IL-10 infusion can prevent lethal endotoxic shock. Mice deficient in the production of IL-10 (IL10T) were used to investigate the regulatory role of IL-10 in the responses to LPS in three experimental systems. In a model of acute endotoxic shock, it was found that the lethal dose of LPS for IL10T mice was 20-fold lower than that for wild type (wt) mice suggesting that endogenous IL-10 determines the amount of LPS which can be tolerated without death. The high mortality rate of IL10T mice challenged with modest doses of LPS was correlated to the uncontrolled production of TNF as treatment with anti-TNF antibody (Ab) resulted in 70% survival. Additional studies suggested that IL-10 mediates protection by controlling the early effectors of endotoxic shock (e.g., TNF alpha) and that it is incapable of directly antagonizing the production and/or actions of late appearing effector molecules (e.g., nitric oxide). We also found that IL10T mice were extremely vulnerable to a generalized Shwartzman reaction where prior exposure to a small amount of LPS primes the host for a lethal response to a subsequent sublethal dose. The priming LPS dose for IL10T mice was 100-fold lower than that required to prime wt mice implying that IL-10 is important for suppressing sensitization. In agreement with this assumption, IL-10 infusion was found to block the sensitization step. Interestingly, IL-10 was not the main effector of endotoxin tolerance as IL10T mice could be tolerized to LPS. Furthermore, IL-10 infusion could not substitute for the desensitizing dose of LPS. These results show that IL-10 is a critical component of the host's natural defense against the development of pathologic responses to LPS although it is not responsible for LPS-induced tolerance.

[1]  B. Barton,et al.  Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model , 1993, Infection and immunity.

[2]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[3]  A. Sher,et al.  Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. , 1994, Journal of immunology.

[4]  B. Beutler,et al.  Cachectin/tumor necrosis factor: An endogenous mediator of shock and inflammation , 1986, Immunologic research.

[5]  H. Spits,et al.  Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. , 1992, International immunology.

[6]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[7]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[8]  P. Ghezzi,et al.  Cytokine down-regulation in endotoxin tolerance. , 1993, European cytokine network.

[9]  J. Brozna Shwartzman Reaction , 1990, Seminars in thrombosis and hemostasis.

[10]  R. Watson,et al.  Role of endotoxin in mononuclear phagocyte‐mediated inflammatory responses , 1994, Journal of leukocyte biology.

[11]  J. Haas,et al.  Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. , 1994, The Journal of biological chemistry.

[12]  H. Fahmi,et al.  Selective refractoriness of macrophages to endotoxin‐induced production of tumor necrosis factor, elicited by an autocrine mechanism , 1993, Journal of leukocyte biology.

[13]  Y. Liu,et al.  A receptor for interleukin 10 is related to interferon receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Herrmann,et al.  CD14 and tolerance to lipopolysaccharide: biochemical and functional analysis. , 1993, Immunology.

[15]  J. Abrams,et al.  Strategies of Anti‐Cytokine Monoclonal Antibody Development: Immunoassay of IL‐10 and IL‐5 in Clinical Samples , 1992, Immunological reviews.

[16]  R. Coffman,et al.  Interleukin‐4 and interleukin‐10 synergize to inhibit cell‐mediated immunity in vivo , 1993, European journal of immunology.

[17]  S. E. Greisman,et al.  Mechanisms of endotoxin tolerance. I. Relationship between tolerance and reticuloendothelial system phagocytic activity in the rabbit. , 1963 .

[18]  H. Schmidt,et al.  Enzymatic formation of nitrogen oxides from L-arginine in bovine brain cytosol. , 1989, Biochemical and biophysical research communications.

[19]  P. Vandenabeele,et al.  Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemia , 1994, European journal of immunology.

[20]  T. Ikejima,et al.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.

[21]  G. Trinchieri,et al.  Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma- production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells , 1993, The Journal of experimental medicine.

[22]  H. Langstein,et al.  Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. , 1992, Journal of immunology.

[23]  H. Heremans,et al.  Regulation by interferons of the local inflammatory response to bacterial lipopolysaccharide. , 1987, Journal of immunology.

[24]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.

[25]  J. Jenkins,et al.  The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. , 1994, Lymphokine and cytokine research.

[26]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor , 1990, Nature.

[27]  G. Constantin,et al.  Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide , 1993, The Journal of experimental medicine.

[28]  C. Dinarello,et al.  A specific receptor antagonist for interleukin 1 prevents Escherichia coli‐induced shock in rabbits , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  G. Fantuzzi,et al.  Early down-regulation of TNF production by LPS tolerance in human monocytes: comparison with IL-1 beta, IL-6, and IL-8. , 1993, Lymphokine and cytokine research.

[30]  T. Mosmann,et al.  IL-10 inhibits cytokine production by activated macrophages. , 1991, Journal of immunology.

[31]  S. Moncada,et al.  Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-alpha and IL-1-beta. , 1994, Immunology.

[32]  M. Howard,et al.  Interleukin 10 protects mice from lethal endotoxemia , 1993, The Journal of experimental medicine.

[33]  S. Moncada,et al.  The Role of Nitric Oxide in Endotoxic Shock: Effects of NG‐Monomethyl‐L‐Arginine , 1992, Journal of cardiovascular pharmacology.

[34]  A. Billiau Gamma-interferon: the match that lights the fire? , 1988, Immunology today.

[35]  A. Billiau,et al.  Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice , 1990, The Journal of experimental medicine.

[36]  A. Billiau,et al.  Essential role for natural killer cells in the lethal lipopolysaccharide‐induced Shwartzman‐like reaction in mice , 1994, European journal of immunology.

[37]  C. Dinarello,et al.  Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. , 1993, JAMA.

[38]  D. Leroy,et al.  IFN-gamma involvement in the severity of gram-negative infections in mice. , 1993, Journal of immunology.

[39]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[40]  G. Trinchieri,et al.  Interleukin 10 (IL-10) Inhibits Human Lymphocyte Interferon 3,-Production by Suppressing Natural Killer Cell Stimulatory Factor/IL-12 Synthesis in Accessory Cells By Annalisa D'Andrea, Miguel Aste-Amezaga, , 1993 .

[41]  R. Coffman,et al.  Interleukin‐4 and interleukin‐10 synergize to inhibit cell‐mediated immunity in vivo , 1993, European journal of immunology.

[42]  C. Dinarello The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. , 1991, The Journal of infectious diseases.

[43]  G. Trinchieri,et al.  Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction , 1994, The Journal of experimental medicine.

[44]  J. Adams,et al.  hypotension: Implications for the involvement of nitric oxide , 2022 .

[45]  T. Mosmann,et al.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones , 1989, The Journal of experimental medicine.

[46]  P. Elsbach,et al.  Bactericidal/permeability increasing protein and host defense against gram-negative bacteria and endotoxin. , 1993, Current opinion in immunology.

[47]  J. Adams,et al.  Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. , 1990, Biochemical and biophysical research communications.

[48]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6 , 1992 .

[49]  L. Steinman,et al.  Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen , 1993, Nature.